No information is available on the clinical use of bortezomib during breastfeeding. Because bortezomib is 83% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of up to 193 hours, the manufacturer recommends that breastfeeding be discontinued during bortezomib therapy and for 2 months after the last dose.
关于硼替佐米在母乳喂养期间的临床应用尚无可用信息。由于硼替佐米与血浆蛋白的结合率为83%，其在乳汁中的含量可能较低。然而，鉴于其对母乳喂养婴儿的潜在毒性以及长达193小时的半衰期，制造商建议在硼替佐米治疗期间及最后一剂后2个月内停止母乳喂养。
